Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis

Annals of Intensive Care

Volumn 6, Issue 1, 2016, Pages

  Glas, Gerie J ^a   Serpa Neto, Ary ^b,c   Horn, Janneke ^a   Cochran, Amalia ^d   Dixon, Barry ^e   Elamin, Elamin M ^f   Faraklas, Iris ^d   Dissanaike, Sharmila ^g   Miller, Andrew C ^h,i   Schultz, Marcus J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Administration; Anticoagulants; Heparin; Humans; Inhalation; Intensive care; Mechanical ventilation

Indexed keywords

HEPARIN;

ARTIFICIAL VENTILATION; EMBASE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG INJURY; MEDLINE; META ANALYSIS; MORTALITY; NEBULIZATION; PATIENT CODING; PRIORITY JOURNAL; REVIEW; SCOPUS; VENTILATED PATIENT; WEB OF SCIENCE;

EID: 84963770915     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/s13613-016-0138-4     Document Type: Review

References (69)

1. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161(2 Pt 1):454–62.
2. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003;31(4 Suppl):S213–20. doi:10.1097/01.CCM.0000057846.21303.AB.
3. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest. 1989;84(2):695–705. doi:10.1172/JCI114217.
4. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24(1):33–44. doi:10.1055/s-2007-995821.
5. Levi M, Schultz MJ, Rijneveld AW, Van Der Poll T. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med. 2003;31(4 Suppl):S238–42. doi:10.1097/01.CCM.0000057849.53689.65.
6. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax. 2004;59(2):130–5.
7. Hofstra JJ, Vlaar AP, Knape P, Mackie DP, Determann RM, Choi G, et al. Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma. J Trauma. 2011;70(6):1389–97. doi:10.1097/TA.0b013e31820f85a7.
8. Schultz MJ, Determann RM, Royakkers AA, Wolthuis EK, Korevaar JC, Levi MM. Bronchoalveolar activation of coagulation and inhibition of fibrinolysis during ventilator-associated lung injury. Crit Care Res Pract. 2012;2012:961784. doi:10.1155/2012/961784.
9. Hofstra JJ, Haitsma JJ, Juffermans NP, Levi M, Schultz MJ. The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost. 2008;34(5):475–84. doi:10.1055/s-0028-1092878.
10. International Consensus Conferences in Intensive Care Medicine. Ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societe de Reanimation de Langue Francaise, and was approved by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 1999;160(6):2118–24.
11. Bastarache JA, Ware LB, Bernard GR. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27(4):365–76. doi:10.1055/s-2006-948290.
12. Castro CY. ARDS and diffuse alveolar damage: a pathologist’s perspective. Semin Thorac Cardiovasc Surg. 2006;18(1):13–9. doi:10.1053/j.semtcvs.2006.02.001.
13. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med. 2000;28(9 Suppl):S77–80.
14. Schultz MJ, Dixon B. A breathtaking and bloodcurdling story of coagulation and inflammation in acute lung injury. J Thromb Haemost. 2009;7(12):2050–2. doi:10.1111/j.1538-7836.2009.03639.x.
15. Seeger W, Stohr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol. 1985;58(2):326–38.
16. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med. 2003;31(4 Suppl):S329–36. doi:10.1097/01.CCM.0000057912.71499.A5.
17. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax. 1998;53(10):815–7.
18. Idell S. Anticoagulants for acute respiratory distress syndrome: can they work? Am J Respir Crit Care Med. 2001;164(4):517–20.
19. Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ. Nebulized anticoagulants for acute lung injury—a systematic review of pre-clinical and clinical investigations. Crit Care. 2012;16(2):R70. doi:10.1186/cc11325.
20. Miller AC, Elamin EM, Suffredini AF. Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med. 2014;42(2):413–9.
21. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47. doi:10.1001/jama.290.2.238.
22. Afshari A, Wetterslev J, Brok J, Moller AM. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2008;3:CD005370. doi:10.1002/14651858.CD005370.pub2.
23. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709. doi:10.1056/NEJM200103083441001.
24. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003;29(6):894–903. doi:10.1007/s00134-003-1731-1.
25. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24(7):663–72.
26. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med. 2009;37(4):1185–96. doi:10.1097/CCM.0b013e31819c06bc.
27. Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care. 2009;13(2):R36. doi:10.1186/cc7747.
28. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178(6):618–23. doi:10.1164/rccm.200803-419OC.
29. Marti-Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev. 2012;12:CD004388. doi:10.1002/14651858.CD004388.pub6.
30. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64. doi:10.1056/NEJMoa1202290.
31. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–78.
32. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2011;183(11):1561–8. doi:10.1164/rccm.201007-1167OC.
33. Bendstrup KE, Jensen JI. Inhaled heparin is effective in exacerbations of asthma. Respir Med. 2000;94(2):174–5. doi:10.1053/rmed.1999.0677.
34. Monagle K, Ryan A, Hepponstall M, Mertyn E, Monagle P, Ignjatovic V, et al. Inhalational use of antithrombotics in humans: review of the literature. Thromb Res. 2015;136(6):1059–66. doi:10.1016/j.thromres.2015.10.011.
35. Markart P, Nass R, Ruppert C, Hundack L, Wygrecka M, Korfei M, et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2010;23(3):161–72. doi:10.1089/jamp.2009.0780.
36. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99 m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1653–8.
37. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care. 2010;14(5):445. doi:10.1186/cc9269.
38. Jaques LB, Mahadoo J, Kavanagh LW. Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet. 1976;2(7996):1157–61.
39. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care. 2008;12(3):R64. doi:10.1186/cc6894.
40. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care. 2010;14(5):R180. doi:10.1186/cc9286.
41. Yip LY, Lim YF, Chan HN. Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre. Burns. 2011;37(7):1154–60. doi:10.1016/j.burns.2011.07.006.
42. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928.
43. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi:10.1007/s10654-010-9491-z.
44. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138(3):720–3.
45. Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/acetylcystine therapy. J Burn Care Rehabil. 1998;19(3):210–2.
46. Dixon B, Santamaria D, Campbell J. Nebulized heparin in acute lung injury. J Aerosol Med Pulm Drug Deliv. 2009;22(2):203.
47. Dixon B, Schultz M, Fink JB, Campbell D, Santamaria JD. Nebulised heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomised controlled trial. Am J Respir Crit Care Med. 2011;183. (1 Meeting Abstracts)
48. Elsharnouby NM, Eid HEA, Abou Elezz NF, Aboelatta YA. Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury. A study of different doses. J Crit Care. 2014;29(1):182.e1–4.
49. Glas GJ, Muller J, Binnekade JM, Cleffken B, Colpaert K, Dixon B, et al. HEPBURN—investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial. Trials. 2014;15:91. doi:10.1186/1745-6215-15-91.
50. Holt J, Saffle JR, Morris SE, Cochran A. Use of inhaled heparin/N-acetylcystine in inhalation injury: does it help? J Burn Care Res. 2008;29(1):192–5.
51. Kashefi NS, Nathan JI, Dissanaike S. Does a nebulized heparin/N-acetylcysteine protocol improve outcomes in adult smoke inhalation? Plast Reconstr Surg Glob Open. 2014;2(6):e165. doi:10.1097/gox.0000000000000121.
52. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res. 2009;30(2):249–56.
53. Otremba S, Faris J. Hall Zimmerman L, Barbat S, White M. Inhaled heparin in critically ill patients with smoke inhalation injury. Crit Care Med. 2013;1:A231–2.
54. Rivero A, Elamin E, Nguyen V, Cruse W, Smith D. Can nebulized heparin and N-acetylcysteine reduce acute lung injury after inhalation lung insult? Chest. 2007;132(4):565S.
55. Kashefi N, Dissanaike S. Does a nebulized heparin/N-acetylcysteine protocol improve clinical outcomes in adult patients with inhalation injury? J Burn Care Res. 2013;1:S82.
56. Determann RM, Royakkers A, Wolthuis EK, Vlaar AP, Choi G, Paulus F, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. Crit Care. 2010;14(1):R1. doi:10.1186/cc8230.
57. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med. 2004;32(9):1817–24.
58. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A. Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med. 2005;31(7):922–6. doi:10.1007/s00134-005-2625-1.
59. Serpa NA, Cardoso SO, Manetta JA, Pereira VG, Esposito DC, Pasqualucci MO, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA. 2012;308(16):1651–9. doi:10.1001/jama.2012.13730.
60. Serpa Neto A, Simonis FD, Barbas CS, Biehl M, Determann RM, Elmer J, et al. Association between tidal volume size, duration of ventilation, and sedation needs in patients without acute respiratory distress syndrome: an individual patient data meta-analysis. Intensive Care Med. 2014;40(7):950–7. doi:10.1007/s00134-014-3318-4.
61. Putensen C, Theuerkauf N, Zinserling J, Wrigge H, Pelosi P. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med. 2009;151(8):566–76.
62. Esteban A, Ferguson ND, Meade MO, Frutos-Vivar F, Apezteguia C, Brochard L, et al. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008;177(2):170–7. doi:10.1164/rccm.200706-893OC.
63. Neto A, Barbas C, Raventós A, Canet J, Determann R. Rationale and study design of provent—an international multicenter observational study on practice of ventilation in critically ill patients without ARDS. J Clin Trials. 2013;3:146. doi:10.4172/2167-0870.1000146.
64. Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care. 2010;55(7):837–44.
65. Ari A, Fink JB, Dhand R. Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv. 2012;25(6):319–32. doi:10.1089/jamp.2011.0936.
66. Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008;21(1):45–60. doi:10.1089/jamp.2007.0663.
67. Bendstrup KE, Newhouse MT, Pedersen OF, Jensen JI. Characterization of heparin aerosols generated in jet and ultrasonic nebulizers. J Aerosol Med. 1999;12(1):17–25.
68. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi:10.1136/bmj.c221.
69. Winkelmayer WC, Kurth T. Propensity scores: help or hype? Nephrol Dial Transplant. 2004;19(7):1671–3. doi:10.1093/ndt/gfh104.